Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): May 21, 2010
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
5.02(d)
|
ELECTION
OF DIRECTOR
|
On May
21, 2010, Oramed Pharmaceuticals Inc. (the "Company") appointed Dr. Michael
Berelowitz, MD, as a member of the Company's Board of Directors effective June
1, 2010.
Dr.
Berelowitz is currently Senior Vice President and Head of Clinical Development
and Medical Affairs in the Specialty Care Business Unit at Pfizer, Inc., the
world's largest research-based pharmaceutical company.
The
Company has not yet determined if Dr. Berelowitz will serve on any of its
committees.
As
remuneration for his service as a director, Dr. Berelowitz will receive an
annual fee as the other non-executive directors.
A copy of
the press release announcing the appointment of Dr. Berelowitz is attached to
this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference
herein.
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated May 18, 2010.
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ORAMED PHARMACEUTICALS
INC.
|
|
Dated:
May 21, 2010
|
|
|
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
|
|
|
Nadav
Kidron
|
|
|
|
|
President,
CEO and Director
|
|
Exhibit
Index
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated May 18, 2010.
|